Mark Tepper Net Worth

The estimated Net Worth of Mark Tepper is at least $190 mil dollars as of 14 November 2018. Mark Tepper owns over 10,000 units of LadRx Corp stock worth over $189,936 and over the last 18 years Mark sold CYTR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Tepper CYTR stock SEC Form 4 insiders trading

Mark has made over 5 trades of the LadRx Corp stock since 2007, according to the Form 4 filled with the SEC. Most recently Mark exercised 10,000 units of CYTR stock worth $10,000 on 14 November 2018.

The largest trade Mark's ever made was exercising 75,000 units of LadRx Corp stock on 9 May 2007 worth over $180,750. On average, Mark trades about 21,545 units every 384 days since 2007. As of 14 November 2018 Mark still owns at least 2,110,400 units of LadRx Corp stock.

You can see the complete history of Mark Tepper stock trades at the bottom of the page.

What's Mark Tepper's mailing address?

Mark's mailing address filed with the SEC is ONE INNOVATION DRIVE, , WORCESTER, MA, 01605.

Insiders trading at LadRx Corp

Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson y Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.

What does LadRx Corp do?

Complete history of Mark Tepper stock trades at Corbus Pharmaceuticals Inc y LadRx Corp

LadRx Corp executives and stock owners

LadRx Corp executives and other stock owners filed with the SEC include:

• Steven Kriegsman,
  Chairman of the Board, Chief Executive Officer
• Steven A. Kriegsman,
  Chief Exec. Officer
• John Caloz,
  Chief Financial Officer, Chief Accounting Officer, IR Contact Officer
• John Y. Caloz,
  CFO, Treasurer & Sr. VP
• Louis Ignarro,
  Independent Director
• Joel Caldwell,
  Director
• Earl Brien,
  Director
• Dr. Felix Kratz Ph.D.,
  Sr. VP, Drug Devel.
• Cristina Newman,
  Corp. Sec.
• Terri Stevens,
  Chief Bus. Officer
• Molly Painter,
  Pres of USA and Head of Launch & Commercial Operations
• Molly Carey Poarch,
  Global & U.S. Head of Corp. Communications
• Jennifer K. Simpson,
  Director
• Anita J Chawla,
  Director
• Daniel J Levitt,
  Chief Medical Officer
• Joseph Rubinfeld,
  Director
• Olivia C Ware,
  Chief Commercial Officer
• Douglas Scott Wieland,
  Sr. VP - Drug Development
• Felix Kratz,
  Vice President Drug Discovery
• Herbert H Jr Mcdade,
  
• Alexander L Cappello,
  Director
• Raymond C Jr Carnahan,
  
• Ben Levin,
  Gen.Cnsl/VP Legal Affairs/Secy
• Eric Jay Selter,
  Director
• Cheryl Cohen,
  Director
• Scott Bradford Patterson,
  10% owner
• Marvin R Selter,
  Director
• Richard J Wennekamp,
  Director
• Max Link,
  Director
• David Scott Geyer,
  Sr. V.P. of Manufacturing
• Mitchell K Fogelman,
  Chief Financial Officer
• Jack R Barber,
  Sr VP - Drug Development
• Shi Chung Ng,
  Sr. VP Research & Development
• Matt Natalizio,
  Chief Financial Officer
• Mark Tepper,
  Vice President
• Stephen Snowdy,
  Chief Executive Officer